Cancer, Malaria & TB Vaccines

Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, and P. ovaleP. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease, HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults.

    Related Conference of Cancer, Malaria & TB Vaccines

    November 28-29, 2024

    38th International Conference on Immunology

    Aix-en-Provence, France
    December 12-13, 2024

    5th International Conference on Immunology And Immunotherapy

    Zurich, Switzerland
    June 16-17, 2025

    19th International Conference on European Immunology

    Frankfurt, Germany

    Cancer, Malaria & TB Vaccines Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in